[go: up one dir, main page]

AR060130A1 - FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY - Google Patents

FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Info

Publication number
AR060130A1
AR060130A1 ARP070101241A ARP070101241A AR060130A1 AR 060130 A1 AR060130 A1 AR 060130A1 AR P070101241 A ARP070101241 A AR P070101241A AR P070101241 A ARP070101241 A AR P070101241A AR 060130 A1 AR060130 A1 AR 060130A1
Authority
AR
Argentina
Prior art keywords
igf
formulation
monoclonal antibody
human monoclonal
preparation
Prior art date
Application number
ARP070101241A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR060130A1 publication Critical patent/AR060130A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion está relacionada con una formulacion de anticuerpo monoclonal humano anti-IGF-1R, un proceso para la preparacion y usos del mismo.The present invention is related to a formulation of anti-IGF-1R human monoclonal antibody, a process for the preparation and uses thereof.

ARP070101241A 2006-03-28 2007-03-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY AR060130A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
AR060130A1 true AR060130A1 (en) 2008-05-28

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101241A AR060130A1 (en) 2006-03-28 2007-03-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Country Status (18)

Country Link
EP (1) EP1998806A1 (en)
JP (1) JP2009531371A (en)
KR (1) KR20080104160A (en)
CN (1) CN101410137A (en)
AR (1) AR060130A1 (en)
AU (1) AU2007229554A1 (en)
BR (1) BRPI0709229A2 (en)
CA (1) CA2647111A1 (en)
CL (1) CL2007000797A1 (en)
CR (1) CR10295A (en)
EC (1) ECSP088778A (en)
IL (1) IL193904A0 (en)
MA (1) MA30345B1 (en)
MX (1) MX2008012295A (en)
NO (1) NO20083895L (en)
RU (1) RU2008142359A (en)
TW (1) TW200815029A (en)
WO (1) WO2007110339A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671968A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CA2681743A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
JP2010531340A (en) * 2007-07-10 2010-09-24 エフ．ホフマン−ラ ロシュ アーゲー New formulation
EP2217624A1 (en) * 2007-11-29 2010-08-18 F. Hoffmann-La Roche AG Immunoglobulin aggregates
DK2234600T3 (en) * 2007-12-21 2014-09-08 Hoffmann La Roche ANTIBODY FORMULATION
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
MX2012007676A (en) * 2009-12-29 2012-08-03 Hoffmann La Roche Antibody formulation.
AU2011257219B2 (en) * 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
MX341076B (en) 2011-03-31 2016-08-04 Merck Sharp & Dohme Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
CN102363040B (en) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 Antimicrobial peptide preparation for mucosal tissues
UA117466C2 (en) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. STABLE COMPOSITION IN THE VIEW OF AN ANTIBODY ANTIBODY TO IL-23p19
CN118561989A (en) 2013-04-29 2024-08-30 豪夫迈·罗氏有限公司 FC-receptor binding modified asymmetric antibodies and methods of use
HK1213578A1 (en) 2013-04-29 2016-07-08 豪夫迈‧罗氏有限公司 Human fcrn-binding modified antibodies and methods of use
CN103505729B (en) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 A kind of stable rabies virus human antibody combination preparation
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A kind of pharmaceutical composition containing adalimumab
CN105916880B (en) 2014-01-15 2020-01-17 豪夫迈·罗氏有限公司 Fc region variants with improved protein A binding
US10206878B2 (en) * 2014-05-28 2019-02-19 Nono Inc. Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
AR102198A1 (en) 2014-10-09 2017-02-08 Regeneron Pharma PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
DK3313879T3 (en) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrin receptor antibodies with adapted affinity
CN106999591B (en) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 anti-PD-1 antibody preparation and application thereof in medicine
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
IL309453A (en) 2016-08-16 2024-02-01 Regeneron Pharma Methods for quantitating individual antibodies from a mixture
IL289895B (en) 2016-10-25 2022-09-01 Regeneron Pharma Methods and systems for chromatography data analysis
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
TW202448568A (en) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
BR112021008873A8 (en) 2018-11-07 2023-04-11 Merck Sharp & Dohme FORMULATION
CN114324882B (en) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 Protein stabilizer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056418A1 (en) * 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
SV2007000775A (en) * 2001-01-05 2007-03-15 Pfizer ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
ATE549359T1 (en) * 2003-04-02 2012-03-15 Hoffmann La Roche ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND THEIR USES
PL1610820T5 (en) * 2003-04-04 2014-01-31 Genentech Inc High concentration antibody and protein formulations
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
CN1835975B (en) * 2003-08-13 2012-11-21 辉瑞产品公司 Modified human IGF-1R antibodies

Also Published As

Publication number Publication date
CL2007000797A1 (en) 2008-01-25
IL193904A0 (en) 2011-08-01
AU2007229554A1 (en) 2007-10-04
MA30345B1 (en) 2009-04-01
ECSP088778A (en) 2008-10-31
KR20080104160A (en) 2008-12-01
BRPI0709229A2 (en) 2011-06-28
JP2009531371A (en) 2009-09-03
CA2647111A1 (en) 2007-10-04
EP1998806A1 (en) 2008-12-10
RU2008142359A (en) 2010-05-10
CN101410137A (en) 2009-04-15
WO2007110339A1 (en) 2007-10-04
NO20083895L (en) 2008-10-24
TW200815029A (en) 2008-04-01
MX2008012295A (en) 2008-10-09
CR10295A (en) 2008-10-06

Similar Documents

Publication Publication Date Title
AR060130A1 (en) FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY
ECSP10010295A (en) FORMULATION OF ANTIBODY
MX353706B (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME.
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
CR20120310A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
CR20150625A (en) COMPOSITION UNDERSTANDING ANTIBODY FIXED TO DOMAIN II OF HER2 AND ITS VARIOUS ACIDS
CR20160355A (en) NEUTRALIZING ANTIBODIES OF HUMAN ATOMEGALOVIRUS AND USE OF THE SAME
EA200900040A1 (en) ANTIBODY MOLECULES THAT ASSOCIATE WITH HUMAN IL-17
ECSP13012877A (en) SOLID FORMS SDE 3- (5-AMINO-2-methyl -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND USES
CR10528A (en) PROCESS TO PRODUCE POXVIRUS AND POXVIRUS COMPOSITIONS
CL2019001745A1 (en) Conjugated antibody drug for ablation of hematopoietic stem cells.
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
UY31466A1 (en) MONOCLONAL ANTIBODIES THAT JOIN THE HGM-CSF AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM
AR051484A1 (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR IL - 17 HUMAN
ECSP14000329A (en) MOLECULES THAT ARE ANTIBODIES WITH SPECIFICITY FOR HUMAN OX40
MX353827B (en) Forms of rifaximin and uses thereof.
CR20110466A (en) ANTI-ERBB-3 / ANTI-C-MET ANTI-ERBB ANTIBODIES
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
ECSP088613A (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN IL-6
LT2013015A (en) PHARMACEUTICAL COMPOSITIONS
BR112012032008A2 (en) s100a4 antibodies and therapeutic uses thereof
CR10561A (en) VACCINES FOR MALARIA
ES2408343R1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
EA201200616A1 (en) DERIVATIVES 2-OXO-1-PIRROLIDININILIMIDAZOTHIAADIA ASOL

Legal Events

Date Code Title Description
FA Abandonment or withdrawal